# Kalaris Therapeutics, Inc.: overview KLRS · Nasdaq · CIK 1754068 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/klrs.md) · [Financials](/companies/klrs/financials.md) · [Filings](/companies/klrs/filings.md) · [Insiders](/companies/klrs/insiders.md) Latest reported revenue: [$0](/filings/0001564590-21-005652.md) for period not labelled, three months to 2019-12-31, from the 10-K filed Feb 12, 2021 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001564590-21-005652). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(28.16)](/filings/0001193125-25-277464.md) | not reported | [(2.52)](/filings/0001193125-26-219328.md) | [(0.61)](/filings/0001193125-26-344532.md) | [(0.64)](/filings/0001193125-25-277464.md) | not reported | [(0.46)](/filings/0001193125-26-219328.md) | [(0.48)](/filings/0001193125-26-344532.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | [(7,074) d](/filings/0001193125-26-110659.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.74)](/filings/0000950170-23-002830.md) | [(2.20)](/filings/0000950170-24-031879.md) | [(42.09)](/filings/0000950170-25-035143.md) | [(51.77)](/filings/0001193125-26-110659.md) | [(2.85)](/filings/0001193125-26-110659.md) | | Free cash flow | $m | [(106)](/filings/0000950170-23-002830.md) | not reported | not reported | not reported | [(38.6)](/filings/0001193125-26-110659.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/klrs/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2023-06-27 | [Gilead Sciences, Inc.](/insiders/882095.md) | 10% owner | Purchase (P) | 2,930,870 | $3.75 | $11.0m | [Form 4](/filings/0001062993-23-014111.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $52.4m | 12,881,175 | | Reduced −66,906 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $5.3m | 1,300,000 | | Unchanged | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $2.3m | 572,687 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $1.8m | 435,798 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.6m | 398,712 | | Added +143,364 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $1.5m | 360,000 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.1m | 262,131 | | Added +255,947 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $607.9k | 149,351 | | Added +83,200 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $566.5k | 139,201 | | Added +71,322 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $464.3k | 114,037 | | Added +26,492 | ## Recent filings [All 694 filings](/companies/klrs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:00 ET | [10-Q](/filings/0001193125-26-344532.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344532 | | 2026-08-11 | 08:05 ET | [8-K](/filings/0001193125-26-343477.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343477 | | 2026-07-20 | 08:07 ET | [8-K](/filings/0001193125-26-308382.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-308382 | | 2026-07-17 | 07:05 ET | [8-K](/filings/0001193125-26-306737.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-306737 | | 2026-07-06 | 16:11 ET | [8-K](/filings/0001193125-26-296190.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-296190 | | 2026-06-04 | 16:06 ET | [8-K](/filings/0001193125-26-257388.md) | 5.07 Shareholder vote results | 0001193125-26-257388 | | 2026-05-22 | 19:48 ET | [SCHEDULE 13D/A](/filings/0001699737-26-000012.md) | Ownership report, active investor, amended | 0001699737-26-000012 | | 2026-05-12 | 16:00 ET | [10-Q](/filings/0001193125-26-219328.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219328 | | 2026-05-12 | 08:08 ET | [8-K](/filings/0001193125-26-218240.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218240 | | 2026-04-24 | 16:25 ET | [DEF 14A](/filings/0001193125-26-177362.md) | Proxy statement, period 2026-06-03 | 0001193125-26-177362 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-110659.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1754068 - Tickers: KLRS - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:31 ET. No prices; not investment advice.